What has NICE said?
Enzalutamide (Xtandi) is recommended as a possible treatment for people with metastatic hormone-relapsed prostate cancer who have no or mild symptoms after androgen deprivation treatment has stopped working, and before chemotherapy is needed.
Additional resources
This page was last updated: